Zydus Cadila, a leading pharmaceutical company in India, has developed a needle-free COVID-19 vaccine called Zycov-D. The vaccine has been approved for emergency use by the Indian government and is expected to play a critical role in the fight against COVID-19 in the country. Read more about : rajkotupdates.news : zydus needle free corona vaccine zycov d.
Zycov-D is a DNA vaccine that uses a plasmid to deliver the genetic material of the SARS-CoV-2 virus into human cells. The vaccine is administered using a needle-free injector called the PharmaJet, which uses a high-pressure jet to deliver the vaccine into the muscle tissue.
The needle-free delivery system makes the vaccine more accessible and convenient for patients, as it eliminates the need for needles and syringes. This is especially important in rural areas, where access to medical facilities and trained healthcare professionals may be limited.
Zycov-D has shown promising results in clinical trials, with an efficacy rate of 66.6% against symptomatic COVID-19 cases. The vaccine has also been shown to be effective against the Delta variant of the virus, which has been causing a surge in cases in India and other parts of the world.
The vaccine has been approved for use in adults aged 18 and above, and is administered in three doses given at intervals of 28 days. The vaccine can be stored at temperatures of 2-8°C, making it easier to transport and store than other COVID-19 vaccines that require ultra-cold storage.
The development of Zycov-D is a major milestone in the fight against COVID-19 in India. The vaccine is expected to play a critical role in the country’s vaccination drive, which has been facing several challenges, including vaccine shortages and logistical issues.
The needle-free delivery system of the vaccine is expected to be particularly beneficial in rural areas, where access to medical facilities and trained healthcare professionals may be limited. The vaccine is also expected to help overcome vaccine hesitancy, as the needle-free delivery system is less intimidating and more comfortable for patients.
Zydus Cadila has also announced plans to conduct clinical trials of Zycov-D in children aged 12-18 years, which is a critical demographic in the fight against COVID-19. The company is also working on a two-dose version of the vaccine, which is expected to further improve the accessibility and convenience of the vaccine.
The approval of Zycov-D for emergency use by the Indian government is a significant achievement for Zydus Cadila, which has been working tirelessly to develop a safe and effective vaccine for COVID-19. The vaccine is the first needle-free COVID-19 vaccine to be approved for emergency use in India and is expected to help accelerate the country’s vaccination drive. Read more about : rajkotupdates.news : zydus needle free corona vaccine zycov d.
In conclusion, the development of Zycov-D is a major milestone in the fight against COVID-19 in India. The needle-free delivery system of the vaccine makes it more accessible and convenient for patients, especially in rural areas where access to medical facilities and trained healthcare professionals may be limited.
The vaccine has shown promising results in clinical trials and is expected to play a critical role in India’s vaccination drive. Zydus Cadila’s commitment to developing a safe and effective vaccine for COVID-19 is a testament to the company’s dedication to public health and to the fight against this pandemic.
